The effect of vitamin E on nephropathy complications of diabetic patients

A survey of effect of vitamin E supplement on advanced glycation end products, oxidative stress and inflammatory markers in diabetic nephropathy patients

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2014122020374N1

Enrollment

Registered

2015-05-06

Start date

2015-03-05

Completion date

Unknown

Last updated

2019-11-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

diabetic nephropathy. non-insulin-dependent diabetic melitus with renal complications

Interventions

Intervention 1: Intervention:daily received 1200 IU vitamin E for three months. Intervention 2: control: daily received placebo for three months.

Eligibility

Sex/Gender

All

Age

40 Years to 85 Years

Inclusion criteria

Inclusion criteria: Patient with diabetic nephropathy Aged 40 to 85 years Proteinuria level > 0.3 g/24 h with or without circulating levels of serum creatinine.

Exclusion criteria

Exclusion criteria: The consumption of vitamin E supplements within 3 months Patients with uncontrolled diabetes, Pregnant women Those with liver or inflammatory diseases

Design outcomes

Primary

Measure	Time frame
Tumour necrosis factor-alpha (TNF-alpha). Timepoint: Before and three months after intervention. Method of measurement: In serum sample will assessed.by an enzyme-linking immunosorbent assay (ELISA) kit. pg/ml.;Matrix metalloproteinases 9(MMP9). Timepoint: Before and three months after intervention. Method of measurement: In serum sample will assessed by ELISA kit. ng/ml.;Matix metalloproteinas 2(MMP2). Timepoint: Before and three months after intervention. Method of measurement: In serum sample will assessed .by ELISA kit. ng/ml.	—

Measure

Time frame

Tumour necrosis factor-alpha (TNF-alpha). Timepoint: Before and three months after intervention. Method of measurement: In serum sample will assessed.by an enzyme-linking immunosorbent assay (ELISA) kit. pg/ml.;Matrix metalloproteinases 9(MMP9). Timepoint: Before and three months after intervention. Method of measurement: In serum sample will assessed by ELISA kit. ng/ml.;Matix metalloproteinas 2(MMP2). Timepoint: Before and three months after intervention. Method of measurement: In serum sample will assessed .by ELISA kit. ng/ml.

—

Secondary

Measure	Time frame
Advanced glycation end products (AGEs). Timepoint: Before and three months after intervention. Method of measurement: In serum sample will assessed .By fluorescence method.;Vitamin E. Timepoint: Before and three months after intervention. Method of measurement: Enzymatic kits.;Creatinine. Timepoint: Before and three months after intervention. Method of measurement: Enzymatic kits.;Blood urea nitrogen. Timepoint: Before and three months after intervention. Method of measurement: Enzymatic kits.;Total protein. Timepoint: Before and three months after intervention. Method of measurement: Enzymatic kits.;Fasting plasma glucose. Timepoint: Before and three months after intervention. Method of measurement: Enzymatic kits.;Insulin. Timepoint: Before and three months after intervention. Method of measurement: ELISA kits.;Malondialdehyde. Timepoint: Before and three months after intervention. Method of measurement: Spectrophotometry.;Insulin resistance. Timepoint: Before and three months after intervention. Method of measurement: Calculation using HOMA formula.	—

Measure

Time frame

Advanced glycation end products (AGEs). Timepoint: Before and three months after intervention. Method of measurement: In serum sample will assessed .By fluorescence method.;Vitamin E. Timepoint: Before and three months after intervention. Method of measurement: Enzymatic kits.;Creatinine. Timepoint: Before and three months after intervention. Method of measurement: Enzymatic kits.;Blood urea nitrogen. Timepoint: Before and three months after intervention. Method of measurement: Enzymatic kits.;Total protein. Timepoint: Before and three months after intervention. Method of measurement: Enzymatic kits.;Fasting plasma glucose. Timepoint: Before and three months after intervention. Method of measurement: Enzymatic kits.;Insulin. Timepoint: Before and three months after intervention. Method of measurement: ELISA kits.;Malondialdehyde. Timepoint: Before and three months after intervention. Method of measurement: Spectrophotometry.;Insulin resistance. Timepoint: Before and three months after intervention. Method of measurement: Calculation using HOMA formula.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr.Esmat Aghadavod Jolfaie

Kashan University of Medical Sciences

Aghadavod_m@Yahoo.com+98 31 5554 0021

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026